{Reference Type}: Journal Article
{Title}: Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations.
{Author}: Sutar AD;Verma RK;Shukla R;
{Journal}: AAPS PharmSciTech
{Volume}: 25
{Issue}: 6
{Year}: 2024 Aug 2
{Factor}: 4.026
{DOI}: 10.1208/s12249-024-02900-z
{Abstract}: Dry powder inhalers (DPIs) are state-of-the-art pulmonary drug delivery systems. This article explores the transformative impact of nanotechnology on DPIs, emphasizing the Quality Target Product Profile (QTPP) with a focus on aerodynamic performance and particle characteristics. It navigates global regulatory frameworks, underscoring the need for safety and efficacy standards. Additionally, it highlights the emerging field of nanoparticulate dry powder inhalers, showcasing their potential to enhance targeted drug delivery in respiratory medicine. This concise overview is a valuable resource for researchers, physicians, and pharmaceutical developers, providing insights into the development and commercialization of advanced inhalation systems.